Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study.

BACKGROUND: Antibodies against citrullinated proteins (ACPA) have been recognised as the most specific serum marker for rheumatoid arthritis. However, serum autoantibodies such as anti-nuclear antibodies have also been detected in the sera of different lymphatic malignancies without accompanying rhe...

Full description

Bibliographic Details
Main Authors: Gunter Assmann, Klara Shihadeh, Viola Poeschel, Niels Murawski, Jutta Conigliarou, Mei Fang Ong, Michael Pfreundschuh
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3917867?pdf=render
id doaj-67569d3822fc4adc953cd25bd7cd3666
record_format Article
spelling doaj-67569d3822fc4adc953cd25bd7cd36662020-11-24T21:50:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0192e8817710.1371/journal.pone.0088177Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study.Gunter AssmannKlara ShihadehViola PoeschelNiels MurawskiJutta ConigliarouMei Fang OngMichael PfreundschuhBACKGROUND: Antibodies against citrullinated proteins (ACPA) have been recognised as the most specific serum marker for rheumatoid arthritis. However, serum autoantibodies such as anti-nuclear antibodies have also been detected in the sera of different lymphatic malignancies without accompanying rheumatologic disease. Therefore, we conducted a study to evaluate the prevalence of ACPA in diffuse large B-cell non-Hodgkin lymphoma (DLBCL). METHODS: Sera of 395 DLBCL patients and 258 age-matched healthy controls were investigated to evaluate the prevalence of ACPA and RF. ACPA-positive data were stratified into subgroups of RF positivity and established prognostic parameters for DLBCL, including overall survival. In addition, the ACPA serum concentrations levels were compared to an ACPA-positive RA cohort (n = 175). The statistics were performed with χ2 test and Mann- Whitney-U test; Kaplan-Meyer curves (log rank test) were used to analyse the overall survival. P-value <0.05 was statistically significant. RESULTS: ACPA, but not RF, occurred significantly more frequently in the sera of DLBCL patients than in healthy controls (3.5% versus 0.8%, p = 0.030). However, the ACPA serum concentration levels were significantly lower than in RA patients (median 10.4 versus 124.1 U/ml, p = 0.0001). After subgroup stratification, ACPA positivity in DLBCL was significantly associated with male gender (4.4% versus 0%, p = 0.022; odds ratio 1.046, CI 1.014-1.079) and with RF-IgM seropositivity (1.77% versus 0%, p = 0.043), but not with prognostic parameters for DLBCL. CONCLUSIONS: DLBCL is associated with a significantly higher prevalence of ACPA, with an increased prevalence in male patients, and simultaneous RF-IgM positivity. However, ACPA is not prognostic for DLBCL. The prevalence of RF-IgM, -IgA, or -IgG did not differ from healthy controls.http://europepmc.org/articles/PMC3917867?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Gunter Assmann
Klara Shihadeh
Viola Poeschel
Niels Murawski
Jutta Conigliarou
Mei Fang Ong
Michael Pfreundschuh
spellingShingle Gunter Assmann
Klara Shihadeh
Viola Poeschel
Niels Murawski
Jutta Conigliarou
Mei Fang Ong
Michael Pfreundschuh
Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study.
PLoS ONE
author_facet Gunter Assmann
Klara Shihadeh
Viola Poeschel
Niels Murawski
Jutta Conigliarou
Mei Fang Ong
Michael Pfreundschuh
author_sort Gunter Assmann
title Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study.
title_short Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study.
title_full Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study.
title_fullStr Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study.
title_full_unstemmed Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study.
title_sort prevalence of anti-citrullinated protein antibodies (acpa) in patients with diffuse large b-cell lymphoma (dlbcl): a case-control study.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description BACKGROUND: Antibodies against citrullinated proteins (ACPA) have been recognised as the most specific serum marker for rheumatoid arthritis. However, serum autoantibodies such as anti-nuclear antibodies have also been detected in the sera of different lymphatic malignancies without accompanying rheumatologic disease. Therefore, we conducted a study to evaluate the prevalence of ACPA in diffuse large B-cell non-Hodgkin lymphoma (DLBCL). METHODS: Sera of 395 DLBCL patients and 258 age-matched healthy controls were investigated to evaluate the prevalence of ACPA and RF. ACPA-positive data were stratified into subgroups of RF positivity and established prognostic parameters for DLBCL, including overall survival. In addition, the ACPA serum concentrations levels were compared to an ACPA-positive RA cohort (n = 175). The statistics were performed with χ2 test and Mann- Whitney-U test; Kaplan-Meyer curves (log rank test) were used to analyse the overall survival. P-value <0.05 was statistically significant. RESULTS: ACPA, but not RF, occurred significantly more frequently in the sera of DLBCL patients than in healthy controls (3.5% versus 0.8%, p = 0.030). However, the ACPA serum concentration levels were significantly lower than in RA patients (median 10.4 versus 124.1 U/ml, p = 0.0001). After subgroup stratification, ACPA positivity in DLBCL was significantly associated with male gender (4.4% versus 0%, p = 0.022; odds ratio 1.046, CI 1.014-1.079) and with RF-IgM seropositivity (1.77% versus 0%, p = 0.043), but not with prognostic parameters for DLBCL. CONCLUSIONS: DLBCL is associated with a significantly higher prevalence of ACPA, with an increased prevalence in male patients, and simultaneous RF-IgM positivity. However, ACPA is not prognostic for DLBCL. The prevalence of RF-IgM, -IgA, or -IgG did not differ from healthy controls.
url http://europepmc.org/articles/PMC3917867?pdf=render
work_keys_str_mv AT gunterassmann prevalenceofanticitrullinatedproteinantibodiesacpainpatientswithdiffuselargebcelllymphomadlbclacasecontrolstudy
AT klarashihadeh prevalenceofanticitrullinatedproteinantibodiesacpainpatientswithdiffuselargebcelllymphomadlbclacasecontrolstudy
AT violapoeschel prevalenceofanticitrullinatedproteinantibodiesacpainpatientswithdiffuselargebcelllymphomadlbclacasecontrolstudy
AT nielsmurawski prevalenceofanticitrullinatedproteinantibodiesacpainpatientswithdiffuselargebcelllymphomadlbclacasecontrolstudy
AT juttaconigliarou prevalenceofanticitrullinatedproteinantibodiesacpainpatientswithdiffuselargebcelllymphomadlbclacasecontrolstudy
AT meifangong prevalenceofanticitrullinatedproteinantibodiesacpainpatientswithdiffuselargebcelllymphomadlbclacasecontrolstudy
AT michaelpfreundschuh prevalenceofanticitrullinatedproteinantibodiesacpainpatientswithdiffuselargebcelllymphomadlbclacasecontrolstudy
_version_ 1725885182789025792